Towards an SI-Traceable Reference Measurement System for Seven Serum Apolipoproteins Using Bottom-Up Quantitative Proteomics: Conceptual Approach Enabled by Cross-Disciplinary/Cross-Sector Collaboration

• Published in: Clinical chemistry (Baltimore, Md.) Md.), 2021-03, Vol.67 (3), p.478-489
• Main Authors: Cobbaert, Christa M, Althaus, Harald, Begcevic Brkovic, Ilijana, Ceglarek, Uta, Coassin, Stefan, Delatour, Vincent, Deprez, Liesbet, Dikaios, Ioannis, Dittrich, Julia, Hoofnagle, Andrew N, Kostner, Gerhard M, Kronenberg, Florian, Kuklenyik, Zsusanna, Prinzing, Urban, Vesper, Hubert W, Zegers, Ingrid, Ruhaak, L Renee
• Format: Article
• Language: English
• Subjects: Analysis; Apolipoproteins; Arteriosclerosis; Atherosclerosis; Calibration; Cardiovascular disease; Cardiovascular diseases; Dilution; Dyslipidemia; Health risks; Heart diseases; Hierarchies; Identification and classification; Lipid metabolism; Lipids; Mass spectrometry; Mass spectroscopy; Measuring instruments; Methods; Patients; Peptides; Precision medicine; Proteomics; Risk analysis; Risk factors; Scientific imaging; Serum lipids; Spectroscopy; Standardization
• ISSN: 0009-9147; 1530-8561
• DOI: 10.1093/clinchem/hvaa239

Abstract Current dyslipidemia management in patients with atherosclerotic cardiovascular disease (ASCVD) is based on traditional serum lipids. Yet, there is some indication from basic research that serum apolipoproteins A-I, (a), B, C-I, C-II, C-III, and E may give better pathophysiological insight into the root causes of dyslipidemia. To facilitate the future adoption of clinical serum apolipoprotein (apo) profiling for precision medicine, strategies for accurate testing should be developed in advance. Recent discoveries in basic science and translational medicine set the stage for the IFCC Working Group on Apolipoproteins by Mass Spectrometry. Main drivers were the convergence of unmet clinical needs in cardiovascular disease (CVD) patients with enabling technology and metrology. First, the residual cardiovascular risk after accounting for established risk factors demonstrates that the current lipid panel is too limited to capture the full complexity of lipid metabolism in patients. Second, there is a need for accurate test results in highly polymorphic and atherogenic apolipoproteins such as apo(a). Third, sufficient robustness of mass spectrometry technology allows reproducible protein quantification at the molecular level. Fourth, several calibration hierarchies in the revised ISO 17511:2020 guideline facilitate metrological traceability of test results, the highest achievable standard being traceability to SI. This article outlines the conceptual approach aimed at achieving a novel, multiplexed Reference Measurement System (RMS) for seven apolipoproteins based on isotope dilution mass spectrometry and peptide-based calibration. This RMS should enable standardization of existing and emerging apolipoprotein assays to SI, within allowable limits of measurement uncertainty, through a sustainable network of Reference Laboratories.